May 22, 2012

Rethinking Immunotherapy for Brain Tumors

Brain tumor image

Eight companies with immunotherapy approaches for brain tumors

2012 Preview: Cancer Immunotherapy Catalysts

MD Becker Partners' Life Science Digest: 2012 graphic

2012 represents a period with robust news flow for emerging immuno-oncology companies

Cancer Immunotherapy: A Roundtable Discussion

meeting desk

Beyond the approvals of both Provenge and Yervoy, there are a number of additional catalysts that could ignite further interest in the field of cancer immunotherapy.

Ipilimumab Approval Highlights Immunotherapy Renaissance

mab_slide

On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.